Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
about
Critical appraisal of eculizumab for atypical hemolytic uremic syndromeDual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targetsLiver transplantation for aHUS: still needed in the eculizumab era?The global aHUS registry: methodology and initial patient characteristics.Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.Thrombotic microangiopathy caused by oral contraceptives in a kidney transplant recipient.Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.Complement in disease: a defence system turning offensiveAnti-complement-factor H-associated glomerulopathies.Can eculizumab be discontinued in aHUS?: Case report and review of the literatureC3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab.Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection.Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome.Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injuryComplement Dysregulation and Disease: Insights from Contemporary Genetics.Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patientsPlasma exchange for paediatric kidney disease-indications and outcomes: a single-centre experience.Applying complement therapeutics to rare diseases.Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.Atypical hemolytic uremic syndrome: a clinical conundrum.The next generation of therapeutics for chronic kidney diseaseTargeting the complement cascade: novel treatments coming down the pike.Thrombotic microangiopathies: a general approach to diagnosis and management.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature.Complement in Kidney TransplantationOutcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab.Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.
P2860
Q26750692-E21F0191-3752-48FE-8B4B-BDE19FF352CCQ28077955-06F8286B-6412-4942-841C-A54417A4FDA5Q33427846-0A5DC399-95DA-4727-A272-A565C37786F7Q33428291-112D526B-B572-45AA-B49A-ABE6FB1D6AE3Q33430681-78BA9D84-48BE-47F5-A4DB-E6AFC9F4F80DQ33430684-61B9AD80-CF92-4786-9DA1-F1BDF843E2F0Q33430817-6EDA44B2-B60A-4448-AD4D-83774FE6E0C4Q33430882-FAC84346-E044-428B-833E-8A830D2DD996Q33432423-B8954A12-38AA-4BA7-95A4-24895B9EA45EQ33434103-0F97AEAE-0B0D-455D-906B-BAB7D2BD67E3Q33434378-38E80016-C238-4CB6-B7BD-10EA35D584B0Q33435310-42AB0E13-B46B-4F84-BAB5-E41FF13D70F6Q33435451-67E021DF-BE2B-4E54-A949-922FB88A36FCQ33439105-1BE20F17-2893-442B-B656-D591E37A3ABFQ33439109-AD66AD40-8270-4964-860C-6A0029E9E5B5Q33439125-81407343-5C98-4563-ACF9-A3982420D3ACQ33439129-D84019FB-3ACF-491C-91F5-FA0CF5CCFAB3Q33441329-4A67030E-3620-40F6-8701-7D00CACEADC5Q33441408-90987095-B436-4F1A-BDBF-C8E0214FAFD8Q33704263-D9E870CD-4E40-45DE-861D-5FB0DAE97E10Q33705135-9E759F4E-083F-44CA-8C52-3EFA0D2280A8Q33783126-C2E97EE6-7D5E-4B96-A98C-79B084C4DA5DQ35891577-0806C30D-894E-491D-AF4F-7CB1A2E28A69Q36221928-0E1D69BB-D656-4579-9B87-0A8006307998Q36241014-30109821-742A-4393-B650-DCE6C274B46AQ36306747-3213D0A9-6E7B-48AF-B0F2-58C0C1A8347FQ36315497-ECE1E3CC-302D-4D28-B5C5-73049F7ACAA2Q37497101-1A8B33E9-C346-4D0C-9318-5EA3AC31A8C5Q38824060-D0D011D0-A7F1-49F8-BD89-19480F2A6C33Q38845590-DF6234CB-E812-4376-998D-708F7973BFFCQ38850489-EE68ABFB-12BB-4F7D-B135-BB28EE0AF657Q38984066-994DC3C7-80CD-4931-8ED4-1F1EAA79BA1FQ39218839-7B0F64FF-4D14-4919-9C51-5D235BCB81B9Q39229604-7B1C04E3-EEA7-480D-AAB0-5DC820B9CCFCQ39309248-47E41ABA-041A-4B9F-8975-1A0BF559A06BQ39371134-1B811DC5-3D73-47EE-88DF-CFBEA234C7C2Q40096366-70BD40C0-7B3E-4BB4-AE65-683EBABD5BF4Q40654455-4AD49994-8F42-43BC-9A7F-6261E950405CQ42000134-39C9720E-E00C-4E2E-ACF4-750C007F0A78Q42086661-C19F97EE-6C8F-452F-874A-DC51277BD9BC
P2860
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Efficacy and safety of eculizu ...... extensions of phase 2 studies
@ast
Efficacy and safety of eculizu ...... extensions of phase 2 studies
@en
type
label
Efficacy and safety of eculizu ...... extensions of phase 2 studies
@ast
Efficacy and safety of eculizu ...... extensions of phase 2 studies
@en
prefLabel
Efficacy and safety of eculizu ...... extensions of phase 2 studies
@ast
Efficacy and safety of eculizu ...... extensions of phase 2 studies
@en
P2093
P2860
P356
P1433
P1476
Efficacy and safety of eculizu ...... extensions of phase 2 studies
@en
P2093
Antonella Trivelli
Camille L Bedrosian
Chantal Loirat
Christoph Licht
Christophe M Legendre
David J Cohen
Kenneth Douglas
Larry A Greenbaum
Maria Herthelius
Maryvonne Hourmant
P2860
P2888
P304
P356
10.1038/KI.2014.423
P407
P577
2015-02-04T00:00:00Z
P5875
P6179
1034487753